Pharsight

Drugs that contain Colchicine

1. Colcrys patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8097655 TAKEDA PHARMS USA Methods for concomitant administration of colchicine and macrolide antibiotics
Oct, 2028

(4 years from now)

US8093297 TAKEDA PHARMS USA Methods for concomitant administration of colchicine and a second active agent
Oct, 2028

(4 years from now)

US7981938 TAKEDA PHARMS USA Colchicine compositions and methods
Oct, 2028

(4 years from now)

US8415395 TAKEDA PHARMS USA Colchicine compositions and methods
Oct, 2028

(4 years from now)

US8093298 TAKEDA PHARMS USA Methods for concomitant administration of colchicine and macrolide antibiotics
Oct, 2028

(4 years from now)

US8093296 TAKEDA PHARMS USA Methods for concomitant administration of colchicine and macrolide antibiotics
Oct, 2028

(4 years from now)

US7964648 TAKEDA PHARMS USA Methods for concomitant administration of colchicine and a second active agent
Oct, 2028

(4 years from now)

US7964647 TAKEDA PHARMS USA Colchicine compositions and methods
Oct, 2028

(4 years from now)

US8415396 TAKEDA PHARMS USA Colchine compositions and methods
Oct, 2028

(4 years from now)

US7935731 TAKEDA PHARMS USA Methods for concomitant administration of colchicine and macrolide antibiotics
Dec, 2028

(4 years from now)

US7619004 TAKEDA PHARMS USA Methods for concomitant administration of colchicine and macrolide antibiotics
Dec, 2028

(4 years from now)

US7601758 TAKEDA PHARMS USA Methods for concomitant administration of colchicine and macrolide antibiotics in the treatment of gout flares
Feb, 2029

(4 years from now)

US7906519 TAKEDA PHARMS USA Methods for concomitant administration of colchicine and a second active agent
Feb, 2029

(4 years from now)

US7820681 TAKEDA PHARMS USA Methods for concomitant administration of colchicine and a second active agent
Feb, 2029

(4 years from now)

US7915269 TAKEDA PHARMS USA Methods for concomitant administration of colchicine and a second active agent
Feb, 2029

(4 years from now)

US8440722 TAKEDA PHARMS USA Methods for concomitant administration of colchicine and a second active agent
Feb, 2029

(4 years from now)

US8440721 TAKEDA PHARMS USA Methods for concomitant administration of colchicine and a second active agent
Feb, 2029

(4 years from now)

Market Authorisation Date: 29 July, 2009

Treatment: Method of using colchicine for the prophylaxis of gout flares; For the treatment and prophylaxis of gout flares & the treatment of familial mediterranean fever; A method for treatment of gout flares d...

Dosage: TABLET;ORAL

How can I launch a generic of COLCRYS before it's drug patent expiration?
More Information on Dosage

COLCRYS family patents

Family Patents

2. Gloperba patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9907751 ROMEG Composition and method of use of colchicine oral liquid
Nov, 2036

(12 years from now)

US10383820 ROMEG Colchicine drug-to-drug interactions
Nov, 2036

(12 years from now)

US10383821 ROMEG Colchicine drug-to-drug interactions
Nov, 2036

(12 years from now)

US10226423 ROMEG Colchicine drug-to-drug interactions
Dec, 2037

(13 years from now)

Market Authorisation Date: 30 January, 2019

Treatment: A method of prophylactic treatment of gout flares in adults comprises administering to a patient a liquid colchicine oral solution

Dosage: SOLUTION;ORAL

How can I launch a generic of GLOPERBA before it's drug patent expiration?
More Information on Dosage

GLOPERBA family patents

Family Patents

3. Lodoco patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10130585 AGEPHA PHARMA FZ Methods of treating and/or preventing cardiovascular disease
Dec, 2034

(10 years from now)

US10842762 AGEPHA PHARMA FZ Method of treating cardiovascular events using colchicine concurrently with an antiplatelet agent
Jan, 2035

(10 years from now)

US9744144 AGEPHA PHARMA FZ Method of treating cardiovascular events using colchicine concurrently with an antiplatelet agent
Jan, 2035

(10 years from now)

US10265281 AGEPHA PHARMA FZ Treatment or prevention of cardiovascular events via the administration of a colchicine derivative
Jan, 2035

(10 years from now)

US10206891 AGEPHA PHARMA FZ Method of treating cardiovascular events using colchicine concurrently with an antiplatelet agent
Jan, 2035

(10 years from now)

US11026901 AGEPHA PHARMA FZ Treatment or prevention of cardiovascular events via the administration of a colchicine derivative
Jan, 2035

(10 years from now)

US11026900 AGEPHA PHARMA FZ Treatment or prevention of cardiovascular events via the administration of a colchicine derivative
Jan, 2035

(10 years from now)

US11026899 AGEPHA PHARMA FZ Treatment or prevention of cardiovascular events via the administration of a colchicine derivative
Jan, 2035

(10 years from now)

Market Authorisation Date: 16 June, 2023

Treatment: A method of treating cardiovascular disease; A method of treating and/or reducing the risk of inflammation, atherosclerotic vascular disease, and cholesterol crystal induced inflammation within athero...

Dosage: TABLET;ORAL

More Information on Dosage

LODOCO family patents

Family Patents

4. Mitigare patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9675613 HIKMA INTL PHARMS Methods of colchicine administration
Aug, 2033

(9 years from now)

US9789108 HIKMA INTL PHARMS Methods of colchicine administration
Aug, 2033

(9 years from now)

US9555029 HIKMA INTL PHARMS Methods of colchicine administration
Aug, 2033

(9 years from now)

US9399036 HIKMA INTL PHARMS Methods of colchicine administration
Aug, 2033

(9 years from now)

US8927607 HIKMA INTL PHARMS Methods of colchicine administration
Aug, 2033

(9 years from now)

Market Authorisation Date: 26 September, 2014

Treatment: Method of using colchicine for the prophylaxis of gout flares

Dosage: CAPSULE;ORAL

How can I launch a generic of MITIGARE before it's drug patent expiration?
More Information on Dosage

MITIGARE family patents

Family Patents